Human herpesvirus-6 (HHV6) is a DNA virus that is a well-known causative agent of exanthema subitum in infants and can give rise to an infectious mononucleosis-like syndrome in adults. 1 More than 90% of the general population has been infected by HHV6. Emerging evidence suggests that HHV6 is an opportunistic and potentially life-threatening pathogen, which is a significant consequence of allogeneic hematopoietic stem cell transplantation (allo-HSCT) immunosuppression. HHV6 reactivation may cause post-transplant acute limbic encephalitis (PALE). Approximately 2% of all HSCT patients develop post-transplant HHV6 encephalitis, 2 which occurs much more frequently (~10% of the time) following umbilical cord blood transplantation (UCBT). 2, 3 HHV6 encephalitis should be suspected in patients who present imaging signal intensity abnormalities in the hippocampal formation and amygdala, and of limbic structures outside of the medial temporal lobe. 4 Recent reports seem to identify UCBT as a risk factor for developing HHV6-associated PALE, 5 potentially due to immune immaturity and the absence of HHV6-specific T-memory cells in the umbilical cord blood. [6] [7] [8] In the current study, we report the case of a 25-year-old patient, suffering from refractory AML, who developed severe PALE after mismatched double UCBT and was successfully treated with ganciclovir. We then discuss the epidemiological, clinical and therapeutic features of this very serious HHV6 reactivation and compare them with the published data.
A 25-year-old man with no relevant medical history was admitted to our cancer centre in June 2013 in the leukaemia unit, in the context of the relapse of an acute erythroblastic leukaemia (AML-M6). Initially and at relapse, conventional cytogenetics and molecular analysis of the bone marrow revealed normal karyotype and FLT3-ITD mutation. In September 2012, the induction chemotherapy contained daunorubicin (60 mg/m 2 ) and high-dose cytarabine (HDAC; 2000 mg/m 2 ). After obtaining the first complete haematological remission, the patient, who did not have an HLA-matched related/unrelated donor, received a consolidation chemotherapy consisting of three cycles of clofarabine (30 mg/m 2 ) and cytarabine (1000 mg/m 2 ). Leukaemia relapse occurred 5 months after the end of consolidation chemotherapy. Salvage chemotherapy was initiated on day 1 and contained etoposide (200 mg/m 2 ), cytarabine (500 mg/m 2 ) and mitoxantrone (12 mg/m 2 ). Prophylactic antifungal therapy with posaconazole 600 mg/day was initiated. In our unit we monitor: serum galactomannan levels and blood CMV quantitative PCR twice a week, stool cultures weekly and plasma posaconazole level weekly. Computed tomography scan was performed before chemotherapy and in case of persistent neutropenic fever. and blood quantitative PCR assays were positive for HHV6 DNA.
The HHV6 viral load of the patient was 1437 copies/mL at the time of transplant conditioning regimen start, and was 33 000 copies/ mL at the time of diagnosis of limbic encephalitis, before the start of antiviral treatment. Intravenous ganciclovir at 5 mg/kg twice daily was promptly administered to treat the HHV6-associated PALE. HHV6 viral load decreased promptly and became undetectable 12 days after ganciclovir was started and remained under lower limit of detection (o 500 copies/mL) after ganciclovir was stopped. On day +45, the patient developed acute steroid refractory grade 4 gastrointestinal GvHD, which was treated with rabbit thymoglobulin, leading to GvHD improvement but persistent chronic diarrhoea. After 3 weeks of intravenous ganciclovir at 5 mg/kg twice daily, the patient displayed partial resolution of the neurological symptoms and the blood HHV6 quantitative PCR results came back negative. Ganciclovir haematological tolerance was satisfactory and we observed no bone marrow suppression. The patient's brain MRI displayed a reduction of hippocampal hyper intensity (Figure 2 ). Neuropsychologic testing assessed episodic memory problems, difficulties in encoding and learning from mistakes, as well as delayed recall failure. Cognitive functions seemed fragile at the mnemonic level and particularly in the verbal sphere with altered verbal fluency. Word encoding was challenging, hampering word storage and retrieval. Lexical availability was disrupted by repetitions and frontal disturbances. The patient underwent a neuropsychological rehabilitation and is still alive and in complete haematological remission 18 months after transplantation (o 5% blasts without evidence of dysplasia in bone marrow, 41500 neutrophils/μL in peripheral blood and full donor chimerism with a single female cord blood unit and 46 XX karyotype), with a fairly satisfactory recovery of mnemonic functions that allowed him to return to work. HHV6 viraemia was undetectable on day +369. The diagnosis of HHV6 PALE is often based on brain MRI 4 associated with the analysis of HHV6 DNA in blood and CSF.
The MRI typically shows an involvement of the limbic system, with hyper intensities localized in the hippocampal region and the amygdalae. Here, we have presented the case of an HHV6 PALE that clinically presented as a nonspecific encephalopathy, which would likely have been misdiagnosed if appropriate blood and CSF assays had not been performed. Blood HHV6 DNA detection following allogeneic HSCT exists in 40-60% of patients, 9 for whom antiviral treatment is not routinely justified because only a few patients with HHV6 reactivation develop encephalopathy without any clear pathophysiological process. However, PCR detection of HHV6 DNA in CSF associated with brain MRI abnormalities and a clinical diagnosis of nonspecific encephalopathy must lead to the urgent initiation of systemic antiviral treatment, usually based on intravenous ganciclovir or foscarnet sodium.
10,11 Antiviral therapy should be started early to prevent brain damage even if it cannot prevent all cases of HHV6 encephalopathy in allo-HSCT recipients due to the dynamic kinetics of plasma HHV6 viral load. 12, 13 Olson et al.
14 recently reported in a single-centre retrospective study, 94% HHV6 reactivation early after UCBT in 125 patients with a five-time lower incidence of HHV6 encephalitis (≈2% instead of the usual 10% in UCBT recipients). In fact 31 patients, among these 125, promptly received foscarnet contributing probably to the lower rate of neurological disability. Despite its effectiveness, antiviral treatment and prolonged use of ganciclovir, valganciclovir or foscarnet may cause serious side effects such as myelosuppression and renal toxicity, which might affect mortality. In 2010, Mori et al. 15 retrospectively assessed 228 allo-HSCT recipients in a single institution and observed an increased incidence of HHV6 PALE in recipients who underwent two or more UCBTs (28.6%). This finding suggested that these 'high-risk' patients could potentially be candidates for prophylactic administration of antiviral agents. At present, there is still no consensus on the indications for initiating antiviral HHV6 treatment, on the potential impact of a delayed initiation or on the optimal duration of treatment. Early diagnosis and treatment might be essential to limit the inevitable hippocampal atrophy, and thus the memory loss and epileptic consequences that may result. This is the reason why HHV6 viraemia monitoring is now a part of our local recommendations for UCBT recipients. Indeed 80% of those who survive HHV6 encephalitis, which is now becoming a curable post-transplant complication, suffer from permanent neurological and neuropsychological disability and sequelae, having a marked influence on the quality of life of long-term survivors. 13 Accordingly, it is necessary to identify the risk factors for HHV6 encephalitis and establish methods for prevention of this complication. Prospective studies are also required to determine whether anti-HHV6 therapy (empirical or targeting HHV6 disease) clears HHV6 blood reactivation and influences survival in UCBT recipients. Finally, the natural history of HHV6 infection remains largely obscure and management of HHV6 PALE patients is a major challenge. Prospective studies are needed to define the role of post-transplantation blood HHV6 DNA monitoring, as well as the place of pre-emptive antiviral therapy and its potential role in reducing the occurrence of this very serious neurological complication.
